Clinical TrialMay 14, 2026, 07:32 AM
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Acute Lung Injury
AI Summary
MiNK Therapeutics announced the initiation of a randomized Phase 2 clinical trial for agenT-797, its off-the-shelf allogeneic iNKT cell therapy, in patients with severe acute lung injury (ALI) and hypoxemic respiratory failure. The study, designated C-1300-02, is being conducted in Lviv, Ukraine, in partnership with First Lviv Territorial Medical Union and UNBROKEN Ukraine, with plans to expand to U.S. sites. The trial aims to evaluate clinically meaningful ICU endpoints such as survival, ventilator-free days, and reduction of secondary infections, with preliminary data anticipated in the second half of 2026.
Key Highlights
- MiNK Therapeutics initiated a randomized Phase 2 clinical trial for agenT-797 in patients with severe acute lung injury (ALI).
- The study evaluates agenT-797, an off-the-shelf allogeneic iNKT cell therapy, plus standard of care.
- The trial is being conducted in Lviv, Ukraine, in partnership with First Lviv Medical and UNBROKEN Ukraine, with U.S. sites in parallel.
- Key endpoints include survival, ventilator-free days, ICU recovery, pathogen control, and reduction of secondary infections.
- Preliminary data from the trial are expected in the second half of 2026.
- The study has received authorization from the Ministry of Health of Ukraine and is supported by an active U.S. IND.
Price Impact
More from INKT